Radioisotopes in the treatment of bone metastases

Annals of Medicine

Volumn 29, Issue 1, 1997, Pages 31-35

  Ben Josef, Edgar ^a,b   Porter, Arthur T ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Bone metastases; Radionuclide therapy; Radiotherapy; Systemic

Indexed keywords

PHOSPHORUS 32; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89;

BONE METASTASIS; CANCER RADIOTHERAPY; DRUG EFFICACY; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY;

EID: 0031038254     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899708998741     Document Type: Short Survey

References (41)

1. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-94.
2. Malawer MM, Delanet TF. Treatment of metastatic cancer to bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer. Principles & Practice of Oncology, 4th edn. Philadelphia: JB Lipincott, 1993: 2225-44.
3. Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management - a survey from the Eastern Cooperative Oncology Group. Ann Intern Med 1993; 119: 121-6.
4. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330: 592-6.
5. Bhadrwaj S, Holland JF. Chemotherapy of metastatic cancer to bone. Clin Orthop 1982; 169: 28-37.
6. Higinbotham NL, Marcove RC. The managment of pathological fractures. J Trauma 1965; 5: 792-8.
7. Van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987; 2: 983-5.
8. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: the results of the Radiation Therapy Oncology Group. Cancer 1982; 50: 893.
9. Blitzer PH. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer 1985; 55: 1468-72.
10. Salazar OM, Rubin P, Hendrikson FR, et al. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors: final Radiation Therapy Oncology Group report. Cancer 1986; 58: 29.
11. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. Univer Calif Publ Pharmacol 1942; 11: 117-49.
12. Blake GM, Zivanovic MA, McEwan AJ, et al. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986; 12: 447-54.
13. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med 1992; 33: 1316-23.
14. Ben-Josef E, Lucas RD, Vasan S, Porter AT. Selective accumulation of strontium-89 in metastatic deposits in bone; radio-histological correlation. Nucl Med Commun 1995; 16: 457-63.
15. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 1988; 29: 549-57.
16. 89Sr activity in bone metastases. Nucl Med Commun 1995; 16: 452-6.
17. National Council on Radiation Protection Measurements. A Handbook of Radioactivity Measurements Procedure. Washington, D.C., 1978.
18. Tennvall J, Darte L, Lindgren R, El Hassan AM. Palliation of multiple bony metastases from prostatic carcinoma with strontium-89. Acta Oncol. 1988; 27: 365-9.
19. Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 1985; 26: 345-8.
20. Laing AH, Ackery DM, Bayly RJ, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991; 64: 816-22.
21. Robinson RG, Spicer JA, Preston DF, Wegst AV, Martin NL. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 1987; 14: 219-22.
22. Correns HJ, Mebel M, Buchali K, et al. Strontium-89 therapy of bone metastases of carcinoma of the prostate gland. Eur J Nucl Med 1979; 4: 33-5.
23. Firusian N, Mellin P, Schmidt CG. Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976; 116: 764-98.
24. 89Sr compared with external beam and hemibody irradiation: a historical perspective. Cancer Invest 1989; 7: 139-69.
25. Robinson RG, Preston DF, Baxter KG, Susing RW, Spicer JA. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 1993; 20 (Suppl. 2): 44-8.
26. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991; 27: 954-8.
27. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-13.
28. Bolger JJ, Dearnaley DP, Kirk D, et al. Strontium-89 Metastron versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol 1993; 20 (Suppl. 2): 32-3.
29. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
30. Friedell HL, Storaasli JP. The use of radioactive phosphorus in the treatment of carcinoma of the breast with wide-spread metastases to bone. Am J Roentgenol 1950; 64: 559-75.
31. Silberstein EB. The treatment of painful osseous metastases with phosphorus-32 labeled phosphates. Semin Oncol 1993; 20 (Suppl. 2): 10-21.
32. Landaw SA. Acute leukemia in polycytemia vera. Semin Hematol 1986; 23: 156-65.
33. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35: 63-9.
34. Eary JF, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34(7): 1031-6.
35. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34: 1839-44.
36. De Klerk JM, Van Dijk A, Van het Schip AD, Zonnenberg BA, Van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992; 33: 646-51.
37. Maxon HR, Thomas SR, Hertzberg VA, et al. Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases. Semin Nucl Med 1992; 22: 33-40.
38. Maxon HR, Schroder LE, Hertzberg VA, et al. Re-186 (Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991; 32: 1877-81.
39. Buchali K, Correns HJ, Schuerer M, et al. Results of a double-blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma Eur J Nucl Med 1988; 14: 349-51.
40. Mertens WC, Porter AT, Ried RH, Powe JE. Strontium-89 and low-dose cisplatinum for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 1992; 33: 1437-43.
41. Turner JH, Claringbold PG, Martindale AA, et al. Samarium-153 EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastases. Eur J Nucl Med 1992; 16: S125 (Abstract).